- Home
- MURA vs MRSN Comparison
MURA vs MRSN Comparison
Compare MURA & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MURA
- MRSN
- Stock Information
- Founded
- MURA 2013
- MRSN 2001
- Country
- MURA Ireland
- MRSN United States
- Employees
- MURA N/A
- MRSN N/A
- Industry
- MURA
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- MURA
- MRSN Health Care
- Exchange
- MURA Nasdaq
- MRSN Nasdaq
- Market Cap
- MURA 35.7M
- MRSN 37.0M
- IPO Year
- MURA N/A
- MRSN 2017
- Fundamental
- Price
- MURA $2.08
- MRSN $7.33
- Analyst Decision
- MURA Strong Buy
- MRSN Strong Buy
- Analyst Count
- MURA 3
- MRSN 3
- Target Price
- MURA $12.00
- MRSN $33.00
- AVG Volume (30 Days)
- MURA 497.8K
- MRSN 90.2K
- Earning Date
- MURA 08-04-2025
- MRSN 08-13-2025
- Dividend Yield
- MURA N/A
- MRSN N/A
- EPS Growth
- MURA N/A
- MRSN N/A
- EPS
- MURA N/A
- MRSN N/A
- Revenue
- MURA N/A
- MRSN $34,769,000.00
- Revenue This Year
- MURA N/A
- MRSN N/A
- Revenue Next Year
- MURA N/A
- MRSN N/A
- P/E Ratio
- MURA N/A
- MRSN N/A
- Revenue Growth
- MURA N/A
- MRSN 16.14
- 52 Week Low
- MURA $0.95
- MRSN $5.21
- 52 Week High
- MURA $4.74
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- MURA 52.06
- MRSN 49.85
- Support Level
- MURA $2.05
- MRSN $6.63
- Resistance Level
- MURA $2.09
- MRSN $7.25
- Average True Range (ATR)
- MURA 0.01
- MRSN 0.51
- MACD
- MURA 0.02
- MRSN 0.02
- Stochastic Oscillator
- MURA 62.50
- MRSN 44.71
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.